Sharemaestro Newsreel

BioAffinity Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

BioAffinity Technologies, Inc. has released its earnings results for the second quarter and six months ending June 30, 2026. For the second quarter, the company saw an increase in sales to USD 1.51 million compared to USD 1.27 million a year ago, while reducing …

Press Release: BioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath(R) Lung

BioAffinity Technologies announced its financial results for the second quarter of 2026, highlighting strong commercial growth for its CyPath® Lung diagnostic. The company reported a significant increase in test volumes and revenue compared to the previous year, driven by expanding insurance coverage and successful …

Mettler-Toledo International, I (MTD) Stock forecasts

Mettler-Toledo International Inc. (MTD) beat consensus earnings and raised guidance for the second consecutive time. The company supplies weighing and precision instruments to various industries, with a significant portion of sales coming from life sciences, industrial, and food retail sectors.

Quest Diagnostics Inc (DGX) Stock News Today

This article from TradingKey provides a news page for Quest Diagnostics Inc (DGX) stock. It includes current stock performance metrics like price, market cap, and P/E ratio. The page indicates that more news will be coming soon regarding DGX stock.

Waters Corporation 2026 Q2 - Results - Earnings Call Presentation (NYSE:WAT) 2026-08-07

Fulgent Genetics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:FLGT) 2026-08-07

This article presents the slide deck published by Fulgent Genetics, Inc. in conjunction with their Q2 2026 earnings call. The content is provided by Seeking Alpha's transcripts team, which publishes numerous quarterly earnings calls. The aim is to share transcript-related developments with readers.

Twist Bioscience Corporation 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:TWST) 2026-08-07

Twist Bioscience Corporation (NASDAQ: TWST) released its Q3 2026 earnings call presentation. The company reported an EPS of -$0.56, missing estimates by $0.38, while revenue reached $118.38M, surpassing expectations by $3.83M and representing a 23.24% year-over-year increase. This presentation was published in conjunction with …

Qiagen N.V. Stock 12‑Month Price Target Raised to $44.52, Implies 7% Upside

Qiagen N.V.'s average price target has been increased from $43.87 to $44.52 by 17 analysts, suggesting a 7% potential upside based on its closing price. The consensus rating remains a "Buy" from 22 covering analysts. Investors can explore more price target data and analyst …

WGS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026

Faruqi & Faruqi, LLP is investigating potential claims against GeneDx Holdings Corp. (NASDAQ: WGS) and reminds investors of the August 3, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that GeneDx and its executives made …

Prenetics Global Limited (PRE) details $1B IM8 customer financing

Prenetics Global Limited (PRE) has detailed a $1 billion growth financing arrangement for its IM8 business with GC Customer Value Arranger, LLC. This agreement allows investors to fund up to $1 billion for IM8's sales and marketing efforts through August 11, 2028. In return, …

Agilent Technologies, Inc. (NYSE:A) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Agilent Technologies, Inc. (NYSE:A) has received a "Moderate Buy" consensus rating from 19 brokerages, with an average 12-month price target of $159.35, exceeding its current share price. The company recently surpassed quarterly earnings expectations with $1.49 EPS and $1.83 billion in revenue, representing a …

Stocks Settle Higher as a Weak Jobs Report Allays Rate Hike Fears

The S&P 500 Index ($SPX) (SPY) closed up +0.62% on Friday, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.28%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.19%. September E-mini S&P futures (ESU26) rose +0.55%, and September E-mini Nasdaq futures (NQU26) …

Veracyte, Inc. $VCYT Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC reduced its stake in Veracyte, Inc. (NASDAQ:VCYT) by 31% in the first quarter, selling 84,255 shares but still retaining 187,368 shares valued at approximately $6 million. Despite this sale, analyst sentiment remains largely positive with a "Moderate Buy" rating and …

CareDx (CDNA): Neil Gagnon and Gagnon entities report 4.4% ownership stake

Neil Gagnon and his affiliated entities, Gagnon Securities LLC and Gagnon Advisors, LLC, have reported a collective ownership stake of 4.4% in CareDx, Inc. (CDNA) common stock through a SCHEDULE 13G/A SEC filing. Neil Gagnon individually beneficially owns 2,293,464 shares (4.4%), while Gagnon Securities …

Danaher Corporation Revenue Breakdown – NYSE:DHR

This article provides a breakdown of Danaher Corporation's (NYSE: DHR) revenue for the last year. The company generated $24.57 billion USD, with its top-performing segment, Diagnostics, contributing $9.94 billion USD. The United States was the largest geographical contributor, accounting for $9.98 billion USD of …

Equity awards tie Illumina, Inc. (ILMN) CCO pay to EPS and TSR

Illumina, Inc. (ILMN) granted its Chief Commercial Officer, Michael C. Sullivan, equity awards on August 5, 2026. These awards include restricted stock units and performance stock units, linking a portion of his compensation directly to the company's financial performance, specifically non-GAAP EPS growth and …

Waters Corp. stock underperforms Friday when compared to competitors despite daily gains

Waters Corp. (WAT) shares advanced 1.79% on Friday, closing at $406.86, despite underperforming its competitors. The company's stock finished 1.76% below its 52-week high of $414.15. The broader market also saw gains, with the S&P 500 Index rising 0.62% and the Dow Jones Industrial …

RADNET Q2 2026 Earnings Preview: Recent $RDNT Insider Trading, Hedge Fund Activity, and More

Medpace Holdings, Inc. (MEDP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Medpace Holdings, Inc. (NASDAQ: MEDP) concerning potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Medpace securities before April 22, 2025, and still hold them, to contact them …

CareDx (NASDAQ: CDNA) insider Peter Maag plans 27,332-share stock sale after option exercise

CareDx, Inc. insider Peter Maag has filed to sell 27,332 shares of Common Stock, which are tied to a stock option exercise dated August 7, 2026. The sale will be executed on NASDAQ through Morgan Stanley Smith Barney LLC’s Executive Financial Services program. The …

Qiagen NV | 6-K: Report of foreign private issuer (related to financial reporting)

This article is a 6-K filing by Qiagen NV, which is a report for a foreign private issuer. These reports are typically related to financial reporting and other significant company updates that are required by regulatory bodies.

IBD 50 Stock Natera Zips Above Profit-Taking Zone On Its Blowout Quarter

Natera stock surged Friday after reporting blowout volume for its cancer-detecting blood test, Signatera, in the second quarter. Continue Reading

Personalis (PSNL) Is Up 6.1% After Q2 Revenue Rises But Losses Deepen - What's Changed

Personalis, Inc. (PSNL) saw its stock rise by 6.1% after reporting a 30% increase in Q2 revenue to US$22.36 million year-over-year, although net losses deepened to US$31.68 million. Despite flat sales for the first half of 2026, the company reaffirmed its full-year revenue guidance …

Cancer Detection Test Receives Regulatory Marking for Use in Great Britain

Personalis Inc. has received UKCA marking for its NeXT Personal Dx test, allowing its clinical use for minimal residual disease detection in Great Britain. This regulatory approval enables pharmaceutical companies to use the platform in multi-national clinical trials, standardizing detection and potentially accelerating drug …

RadNet earnings in focus as profit return looms after Q1 miss

RadNet Inc. is expected to report second-quarter earnings, with analysts anticipating a rebound to profitability at 20 cents per share on revenues of $610 million, following a Q1 loss. Investors will closely watch for resolution of operational challenges and the performance of its digital …

RadNet, Inc. (RDNT) Stock Forecasts

Argus has raised its target price for RadNet Inc. (RDNT) to $73.00, noting the company's role as a national provider of diagnostic imaging services across two segments: Imaging Center and Digital Health. The current stock price for RDNT is $72.39. The article also lists …

Quantinno Capital Management LP Has $5.30 Million Stock Holdings in Qiagen N.V. $QGEN

Quantinno Capital Management LP significantly reduced its stake in Qiagen N.V. by 40.6% in the first quarter, now holding 132,392 shares valued at approximately $5.3 million. Despite this, Qiagen's recent quarterly earnings exceeded expectations, with EPS of $0.62 and revenue of $535 million, and …

PTA-CMS: QIAGEN N.V.: Release of a capital market information

QIAGEN N.V. has filed its Form 6-K Report of Foreign Private Issuer for the quarterly period ended June 30, 2026, with the United States Securities and Exchange Commission (SEC). The document is now accessible on QIAGEN's website. This release provides important capital market information …

QIAGEN N.V. (NYSE: QGEN) tops Q2 EPS outlook and reaffirms 2026 targets

QIAGEN N.V. exceeded its Q2 2026 EPS outlook with adjusted diluted EPS of $0.62, against an outlook of at least $0.60 CER, and reaffirmed its full-year 2026 guidance for net sales growth of about 1-2% CER and adjusted diluted EPS of at least $2.43 …

Natera, Doximity, PubMatic, Airbnb And Other Big Stocks Moving Higher On Friday

Several major stocks, including Natera, Doximity, PubMatic, and Airbnb, saw significant gains on Friday due to better-than-expected quarterly financial results and raised sales guidance. Natera jumped 20.5% after beating loss estimates and exceeding revenue expectations. Doximity climbed 39%, while Airbnb rose 15.8% after both …

Prenetics (Nasdaq: PRE) files F-1 to register 2.36M warrant shares for resale

Prenetics Global Limited (Nasdaq: PRE) has filed an F-1 registration statement to allow for the resale of up to 2.36 million Class A Ordinary Shares by existing holders of Class C "Exchange Warrants." The company will not receive proceeds from the resales but may …

Catalyst Watch: Inflation reads, AMAT earnings, Google Pixel event, and MLB on Netflix

[Lower Manhattan Cityscape] Art Wager/E+ via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY - AUGUST 10 * …

MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Myriad (MYGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Myriad and would like to discuss your legal rights, contact Bragar Eagel …

Medpace Holdings, Inc. SEC Filing (Aug 7, 2026)

This article reports on Medpace Holdings, Inc.'s SEC Form 144 filing on August 7, 2026, detailing a proposed sale of securities. The filing indicates the sale of 795 shares of common stock acquired through stock option exercise on the same date, with an aggregate …

Should You Investigate Medpace Holdings, Inc. (NASDAQ:MEDP) At US$585?

The article discusses whether Medpace Holdings, Inc. (NASDAQ:MEDP) is a good investment at its current share price of US$585. It delves into the company's valuation, considering factors such as its price-to-earnings (P/E) ratio and future growth prospects. The analysis aims to help potential investors …

Biodesix boosts sales, trims loss as diagnostics firm pushes toward profitability

Biodesix Inc. (Nasdaq: BDSX) reported improved top and bottom lines in the second quarter, indicating progress towards profitability. The life-sciences company, which specializes in lung diagnostic tools, has shown consistent efforts to boost sales and reduce losses. This financial improvement positions Biodesix on a …